Notice Information
Notice Title
QF-PCR Assay for the Rapid Aneuploidy Testing of Prenatal, Fetal Tissue and Neonatal Blood Samples
Notice Description
NHS Wales Shared Services Partnership, Procurement Services on behalf of the All Wales Genomics Laboratory wishes to invite suppliers with the capability of supplying a commercial QF-PCR assay for the rapid aneuploidy testing of prenatal, fetal tissue and neonatal blood samples to discuss their solution.
Lot Information
Lot 1
The Reproductive and Neonatal Genomics Services team at the All Wales Genomics Laboratory offers a range of specialist tests as part of investigations performed on prenatal, postnatal and post-mortem tissue samples. The team currently offers a rapid aneuploidy testing service using an in-house QF-PCR assay with considerable staff time required to prepare kits and set-up the testing. The following tests are performed; -Rapid aneuploidy testing for trisomy 13, 18 and 21 and triploidy as a front-line test for all prenatal and pregnancy loss samples and for neonatal samples referred due to a clinical suspicion of a common trisomy -Sex chromosome testing to detect evidence of sex chromosome aneuploidy in prenatal and pregnancy loss samples referred with evidence of fetal cystic hygroma (monosomy X), and for male patients with suspected Klinefelter syndrome (XXY) -A rapid service to determine genotypic sex for foetuses at risk of an X-linked condition or congenital adrenal hyperplasia (CAH) and for neonates with ambiguous genitalia -Maternal cell contamination (MCC) testing of prenatal samples prior to onward testing The laboratory receives approximately 170 prenatal samples, 240 pregnancy loss samples and 75 neonatal samples per annum. The laboratory team intends to procure a commercial QF-PCR assay for the rapid aneuploidy testing of prenatal, fetal tissue and neonatal blood samples on a 3-5 year contract. We anticipate that the tender will be out by late Spring/early Summer 2021, with a view to begin service delivery by January 2022. The main drivers for change are: -To reduce the analysis time by the procurement of a solution with a low requirement for repeat testing -To reduce the hands-on time required for both the technical and analytical aspects of the testing. -To future proof ahead of CE-IVD Directive requirements coming into force for genetic testing Please create a 1-1.5 hour presentation to be delivered remotely via Teams/Skype/Zoom on a mutually convenient time/date between Monday 29th March to Friday 9th April 2021. The presentation should detail how your solution may best meet our needs with time for questions at the end. It should cover the points below as well as giving an overview of the functionality of the assay that would be of benefit to the laboratory: 1.The application of the assay to a range of sample types including; amniotic fluid/prenatal fluids, chorionic villi, fetal tissue/products of conception, neonatal bloods 2.The assay performance on chelex-based DNA preps and sub-standard samples 3.The ability of the assay to detect low level cell lines indicative of mosaicism or maternal cell contamination 4.The microsatellite marker content and chromosome coverage of the available test kits 5.An overview of the technical procedure with an estimation of hands-on time for the PCR set-up 6.Expected failure rate for different sample types and the repeat reflex options which are available 7.The software solutions available and their compatibility with the 3730 genetic analyser and Genemapper v6 8.The ability to mask data within the software solution to reduce identification of incidental findings 9.Costing for each of the test kit options (inclusive of reflex kits) 10.The shelf-life/expiry date of the kits 11.Lead-in time from ordering to receipt of goods Additional information: Please contact Sarah.Anderson@wales.nhs.uk and elle.mcneil@wales.nhs.uk to arrange a meeting to discuss our requirement and present your solution.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-029868
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/004371-2021
- Current Stage
- Planning
- All Stages
- Planning
Procurement Classification
- Notice Type
- Planning Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Not Specified
- Procurement Method Details
- Not specified
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33696000 - Reagents and contrast media
Notice Value(s)
- Tender Value
- Not specified
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 4 Mar 20214 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- 31 May 2021Expired
- Award Date
- Not specified
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Planned
- Lots Status
- Planned
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS WALES SHARED SERVICES PARTNERSHIP-PROCUREMENT SERVICES (HOSTED BY VELINDRE UNIVERSITY NHS TRUST)
- Contact Name
- Not specified
- Contact Email
- rhian.lye@wales.nhs.uk
- Contact Phone
- +44 2921836446
Buyer Location
- Locality
- CARDIFF
- Postcode
- CF14 4TT
- Post Town
- Cardiff
- Country
- Wales
-
- Major Region (ITL 1)
- TLL Wales
- Basic Region (ITL 2)
- TLL5 South East Wales
- Small Region (ITL 3)
- TLL52 Cardiff and Vale of Glamorgan
- Delivery Location
- TLL Wales
-
- Local Authority
- Cardiff
- Electoral Ward
- Heath
- Westminster Constituency
- Cardiff North
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-029868-2021-03-04T16:24:02Z",
"date": "2021-03-04T16:24:02Z",
"ocid": "ocds-h6vhtk-029868",
"description": "NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=108764. (WA Ref:108764)",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-029868",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "QF-PCR Assay for the Rapid Aneuploidy Testing of Prenatal, Fetal Tissue and Neonatal Blood Samples",
"status": "planned",
"classification": {
"scheme": "CPV",
"id": "33696000",
"description": "Reagents and contrast media"
},
"mainProcurementCategory": "goods",
"description": "NHS Wales Shared Services Partnership, Procurement Services on behalf of the All Wales Genomics Laboratory wishes to invite suppliers with the capability of supplying a commercial QF-PCR assay for the rapid aneuploidy testing of prenatal, fetal tissue and neonatal blood samples to discuss their solution.",
"lots": [
{
"id": "1",
"description": "The Reproductive and Neonatal Genomics Services team at the All Wales Genomics Laboratory offers a range of specialist tests as part of investigations performed on prenatal, postnatal and post-mortem tissue samples. The team currently offers a rapid aneuploidy testing service using an in-house QF-PCR assay with considerable staff time required to prepare kits and set-up the testing. The following tests are performed; -Rapid aneuploidy testing for trisomy 13, 18 and 21 and triploidy as a front-line test for all prenatal and pregnancy loss samples and for neonatal samples referred due to a clinical suspicion of a common trisomy -Sex chromosome testing to detect evidence of sex chromosome aneuploidy in prenatal and pregnancy loss samples referred with evidence of fetal cystic hygroma (monosomy X), and for male patients with suspected Klinefelter syndrome (XXY) -A rapid service to determine genotypic sex for foetuses at risk of an X-linked condition or congenital adrenal hyperplasia (CAH) and for neonates with ambiguous genitalia -Maternal cell contamination (MCC) testing of prenatal samples prior to onward testing The laboratory receives approximately 170 prenatal samples, 240 pregnancy loss samples and 75 neonatal samples per annum. The laboratory team intends to procure a commercial QF-PCR assay for the rapid aneuploidy testing of prenatal, fetal tissue and neonatal blood samples on a 3-5 year contract. We anticipate that the tender will be out by late Spring/early Summer 2021, with a view to begin service delivery by January 2022. The main drivers for change are: -To reduce the analysis time by the procurement of a solution with a low requirement for repeat testing -To reduce the hands-on time required for both the technical and analytical aspects of the testing. -To future proof ahead of CE-IVD Directive requirements coming into force for genetic testing Please create a 1-1.5 hour presentation to be delivered remotely via Teams/Skype/Zoom on a mutually convenient time/date between Monday 29th March to Friday 9th April 2021. The presentation should detail how your solution may best meet our needs with time for questions at the end. It should cover the points below as well as giving an overview of the functionality of the assay that would be of benefit to the laboratory: 1.The application of the assay to a range of sample types including; amniotic fluid/prenatal fluids, chorionic villi, fetal tissue/products of conception, neonatal bloods 2.The assay performance on chelex-based DNA preps and sub-standard samples 3.The ability of the assay to detect low level cell lines indicative of mosaicism or maternal cell contamination 4.The microsatellite marker content and chromosome coverage of the available test kits 5.An overview of the technical procedure with an estimation of hands-on time for the PCR set-up 6.Expected failure rate for different sample types and the repeat reflex options which are available 7.The software solutions available and their compatibility with the 3730 genetic analyser and Genemapper v6 8.The ability to mask data within the software solution to reduce identification of incidental findings 9.Costing for each of the test kit options (inclusive of reflex kits) 10.The shelf-life/expiry date of the kits 11.Lead-in time from ordering to receipt of goods Additional information: Please contact Sarah.Anderson@wales.nhs.uk and elle.mcneil@wales.nhs.uk to arrange a meeting to discuss our requirement and present your solution.",
"status": "planned"
}
],
"items": [
{
"id": "1",
"deliveryAddresses": [
{
"region": "UKL"
}
],
"deliveryLocation": {
"description": "All Wales Genomics Laboratory, University Hospital of Wales, Cardiff"
},
"relatedLot": "1"
}
],
"communication": {
"futureNoticeDate": "2021-06-01T00:00:00+01:00"
},
"coveredBy": [
"GPA"
]
},
"parties": [
{
"id": "GB-FTS-7545",
"name": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)",
"identifier": {
"legalName": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)"
},
"address": {
"streetAddress": "2nd Floor, Woodland House, Maes-Y-Coed Rd",
"locality": "Cardiff",
"region": "UK",
"postalCode": "CF14 4TT",
"countryName": "United Kingdom"
},
"contactPoint": {
"telephone": "+44 2921836446",
"email": "rhian.lye@wales.nhs.uk"
},
"roles": [
"buyer",
"centralPurchasingBody"
],
"details": {
"url": "http://nwssp.nhs.wales/ourservices/procurement-services/",
"buyerProfile": "https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
}
],
"buyer": {
"id": "GB-FTS-7545",
"name": "NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)"
},
"language": "en"
}